Article

Proposal for a Value-Based Agreement to Reimburse Anti-obesity Medicines in Traditional Medicare

2025-07-11

Abstract excerpt

Anti-obesity medicines (AOMs), such as glucagon-like peptide-1 (GLP-1) agonists, hold great promise for slowing the chronic disease epidemic in the United States. Treatment with semaglutide and tirzepatide produces substantial weight loss and significant reductions in obesity-related diseases. Prior research shows expanding access to AOMs would generate trillions of dollars in social value to Americans today in th...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 749cce74-7b5b-5baf-8a4d-eb2aff1805df
DOI: 10.1101/2025.07.10.25331289

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Proposal for a Value-Based Agreement to Reimburse Anti-obesity Medicines in Traditional MedicareDOI 10.1101/2025.07.10.25331289Read

Real-World Weight Loss and Telehealth Platform Utilization Patterns of Long-Term GLP-1 Receptor Agonist Treatment of self pay patients : A Retrospective AnalysisSemantic proximity Read

Current status of anti-obesity medications and performance, an EHR based surveySemantic proximity Read

Are Semaglutide and Tirzepatide Cost-Effective for Weight Management? A Systematic Review and Meta-analysisSemantic proximity Read

Estimated Costs of Production Compared with National Prices, for Drugs to Treat Clinical ObesitySemantic proximity Read

Considering Real-World Effectiveness of GLP-1RA Persistence and Outcomes for Weight loss regimes.Semantic proximity Read

The Impact of the Inflation Reduction Act on Investment in Innovative Medicines: A Project- Level AnalysisSemantic proximity Read

Economic Impact of a Precision Nutrition Digital Therapeutic on Employer Health Costs: A Multi-Employer and Multi-Year Claims AnalysisSemantic proximity Read

Clinical efficacy landscaping in genetic obesity: A meta-analysis in Prader Willi syndrome (PWS)Semantic proximity Read

Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight lossSemantic proximity Read

Changes in Healthcare Spending Attributable to Obesity: Payer- and Service-Specific EstimatesSemantic proximity Read

Real-World Effectiveness, Safety, and Use Patterns of GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes: A Nationwide Multicentre Community Pharmacy StudySemantic proximity Read

Pricing Treatments Cost-Effectively When They Have Multiple Indications: Not Just a Simple Threshold AnalysisSemantic proximity Read